Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenazopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.96 |
| ▸ | MEN1 | O00255 | 8/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.96 |
| ▸ | HBB | P68871 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.93 |
| ▸ | USP2 | O75604 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | DRD2 | P14416 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazopyridine SCHEMBL301672 | 1.00 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL5973732 | 1.00 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL14687482 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL28796595 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL26499 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL215655 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL19357 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL29392321 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL302506 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL6661856 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3768668-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2019183367-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-10069071-B2 | Polycyclic aromatic hydrocarbon copolymers | SMARTKEM LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| EP-3039728-B1 | POLYMERIC ORGANIC SEMICONDUCTOR COMPOSITIONS | SMARTKEM LTD (GB) | 2018-07-04 | — | — | EP | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
| EP-1470107-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004089916-A1 | 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | MERCK FROSST CANADA & CO. (CA) | 2003-08-21 | — | — | US | disclosed |
| WO-2003062200-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2003-07-31 | — | — | WO | disclosed |
| EP-1066280-A4 | HALIMIDE, A CYTOTOXIC MARINE NATURAL PRODUCT, AND DERIVATIVES THEREOF | UNIV CALIFORNIA (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1066280-A1 | HALIMIDE, A CYTOTOXIC MARINE NATURAL PRODUCT, AND DERIVATIVES THEREOF | The Regents of the University of California (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6069146-A | Halimide, a cytotoxic marine natural product, and derivatives thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-30 | — | — | US | disclosed |
| WO-1999048889-A1 | HALIMIDE, A CYTOTOXIC MARINE NATURAL PRODUCT, AND DERIVATIVES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | MAPT 4685/4885MEN1 4395/4885KMT2A 1505/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | MAPT 4685/4885MEN1 4395/4885KMT2A 1505/4885 |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | PTGES, PTGIR, PTGER1 | MAPT 4451/4885MEN1 3432/4885KMT2A 3777/4885 |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | MAPT 1495/4885MEN1 4069/4885KMT2A 1219/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | MAPT 4383/4885MEN1 4190/4885KMT2A 1388/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | MAPT 4401/4885MEN1 3524/4885KMT2A 1178/4885 |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | MAPT 4685/4885MEN1 4395/4885KMT2A 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.